2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - New Orleans Theatre B
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Biological Processes, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

705 Preliminary safety and efficacy of IASO208, a first-in-Human in vivo CD20-targeted third-generation CAR-T therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma

Jia Xu, Weijiayi Wang2, Lin Liu3, Liman Su4, Wei Xie5, Jun Fang6, Lu Zhang7, Yong Yu8, Yanhua Tu9, huan he, PhD10, lijuan hou11, Hu Yu, MD12, Yongke Zhang, MD, PhD13, Heng Mei, MD, PhD14
1 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 IASO Biotherapeutics, Shanghai, China
9 IASO Biotherapeutics, Shanghai, China
10 IASO Biotherapeutics, Shanghai, China
11 IASO Biotherapeutics, Shanghai, China
12 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
13 IASO Biotherapeutics, Shanghai, China
14 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background: Monoclonal and bispecific CD20-targeted antibodies have yielded substantial clinical benefits in B-cell non-Hodgkin lymphoma (B-NHL), but their therapeutic efficacy is markedly compromised by short in vivo half-life. While autologous CD19 CAR-T has been well-established for relapsed or refractory (R/R) B-NHL, CD20-targeted CAR-T regimens remain underdeveloped. Therefore, we developed IASO208, a novel first-in-human in vivo CD20-targeted CAR-T product. IASO208 is engineered via third-generation replication-defective lentiviral vectors with mutated cocal glycoprotein pseudotyping, and further optimized with T cell-targeting and activating functional moieties. This study presents the preliminary safety and efficacy of IASO208 in patients with R/R B-NHL.

Methods: Eligible patients were diagnosed with CD20-positive R/R B-NHL, had an ECOG performance status of 0–2, and harbored at least one measurable tumor lesion. IASO208 was administered as a single intravenous infusion without prior leukapheresis and lymphodepletion, following a standard 3+3 dose-escalation study design. Primary endpoints included dose-limiting toxicity (DLT), treatment-emergent adverse events, and other safety profiles. Secondary endpoints encompassed clinical efficacy, PK, and  PD. ClinicalTrials.gov (NCT07309900).

Results: As of August 3, 2026, a total of 9 R/R B-NHL patients (6 DLBCL, 1 THRLBCL, 1 FL, 1 MCL) received IASO208 treatment across three dose levels (3.0-9.0 × 108 transduction units [TUs]).The median patient age was 62 years (range: 32-70 years). Patients had a median of 3 prior lines of systemic therapy, and all subjects had previously received rituximab-based treatment. Prior targeted immunotherapies also included anti-CD19 or anti-CD20 T cell engagers (n=3), sequential CD19/CD22 CAR-T cell therapy (n=1), and CD19 CAR-NK cell therapy (n=2). Most patients (7/9, 77.8%) presented with stage III/IV advanced disease, and 4 patients (44.4%) had extranodal tumor involvement. The median sum of product of diameters (SPD) of target lesions was 3268 mm² (range: 180–26163 mm²), with 3 patients (33.3%) having bulky disease.

The median interval from screening to IASO208 infusion was 19 days (range: 5-22 days). Infusion-related reactions (IRRs) occurred in 8 patients shortly after infusion, and all IRRs resolved completely within 48 hours. PK analysis demonstrated that viral load peaked at 5 minutes post-infusion and remained detectable for up to 2 days. No DLT, treatment-related mortality, or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 1-2 cytokine release syndrome (CRS) occurred in 77.8% of patients, with a median duration of 2 days. Grade 3-4 cytopenias included leukopenia (1/9, 11.1%), neutropenia (3/9, 33.4%), lymphopenia (6/9, 66.7%), anemia (5/9, 55.6%), and thrombocytopenia (2/9, 22.2%), with most recovering to ≤ grade 2 by month 1.

CAR-T cell expansion kinetics were dynamically monitored via ddPCR. The median time to peak CAR-T expansion was 15.5 days (range: 12-17 days), with a median Cmax of 15622 copies/µg DNA (range: 87–46045 copies/µg DNA). CAR-T cells persisted for up to 63 days post-infusion by flow cytometry. During the expansion phase, IASO208 CAR-T cells predominantly exhibited an effector memory phenotype, which underpins its potent anti-tumor activity.

With a median follow-up of 62.0 days (range: 17.0-206.0 days), efficacy was evaluable in 8 patients. IASO208 elicited robust and durable clinical responses in evaluable patients, achieving 3 CR and 4 PR, with an overall response rate (ORR) of 87.5%. Six responding patients experienced continuous response deepening over time, indicating sustained therapeutic potential. Of note, 2 efficacy-evaluable patients with bulky disease achieved confirmed PR at 1-month follow-up, with 98% and 88% shrinkage of their largest target lesions.

Conclusions: As a novel first-in-human in vivo CD20-targeted CAR-T therapy, IASO208 demonstrates a favorable and manageable safety profile, with no grade ≥3 CRS or any grade ICANS observed. It delivers promising clinical efficacy in heavily pretreated R/R B-NHL patients who failed multiple CD20-directed antibody and cellular immunotherapies. Encouraging anti-tumor activity was also validated in high-risk subgroups with bulky disease and extranodal involvement. These findings support that IASO208 is a safe and potent therapeutic candidate for R/R B-NHL patients.

Jia Xu: No relevant conflicts of interest to declare.